Fiserv stock edges up as Clover lands CareCredit expansion — here’s what traders watch next

Fiserv stock edges up as Clover lands CareCredit expansion — here’s what traders watch next

New York, January 14, 2026, 15:08 EST — Regular session

  • Fiserv shares edged up roughly 0.1% in afternoon trading, holding firm against the wider market downturn
  • Synchrony broadened CareCredit’s reach by integrating it further with Fiserv’s Clover platform, now covering over 40,000 providers
  • Investors are eager for the next confirmed earnings date and any news on the turnaround

Fiserv shares edged up Wednesday afternoon, hitting $66.81, even as the S&P 500 ETF slipped roughly 0.8%.

The move was modest, yet the situation remains fragile. Fiserv is working to regain trust after slashing its outlook and shaking up leadership in October, which sparked a record one-day plunge in its stock.

Broader markets dragged lower again. Wall Street’s key indexes dropped for a second day while investors digested patchy results from major banks. “It’s not unusual to see a little bit of a pullback,” said Jake Johnston, deputy CIO at Advisors Asset Management. 1

A company-linked headline lingered in the background. On Monday, Synchrony announced it expanded its CareCredit integration with Clover, Fiserv’s point-of-sale and commerce platform, now covering more than 40,000 health and wellness providers. The upgrade enables the entire financing process—from application to payment—directly on Clover devices. Synchrony executive Beto Casellas called it a “powerful operational advantage.” Fiserv’s Katie Whalen added the partnership should help practices “streamline payment processes and enhance the patient experience.” 2

Payments stocks showed a mixed picture. PayPal gained roughly 1.6%, but Global Payments dipped 0.3%, and Fidelity National Information Services dropped close to 0.9%.

Fiserv came into Wednesday following a rough day. On Tuesday, the stock dropped 2.13% amid a broader market pullback, mirroring a selloff among other payments companies.

The downside remains clear. Financial stocks have felt the heat from policy shifts and rate news, especially concerns over a proposed cap on credit-card interest rates. That’s rattling confidence in consumer-linked payment volumes.

Investors are waiting for Fiserv to announce its next concrete milestone. The company’s investor relations page shows no scheduled events at the moment. 3

Fiserv’s next earnings report is tentatively set for around Feb. 4, according to some calendars, but the company hasn’t officially confirmed a date. Investors will be watching that release closely, especially for any updated guidance. 4

Stock Market Today

South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
Wesfarmers shares closed down 1.33% at A$85.04 on Friday, following a sharp drop in the S&P/ASX 200, which fell 2% for its steepest one-day loss in 10 months. Investors are watching for Australia’s household spending data next week and Wesfarmers’ half-year results due Feb. 19.
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline
Previous Story

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Constellation Software stock tumbles to new 52-week low as investors question acquisition-led growth
Next Story

Constellation Software stock tumbles to new 52-week low as investors question acquisition-led growth

Go toTop